» Articles » PMID: 29621974

Characteristics of a Newly Diagnosed Polish Cohort of Patients with Neurological Manifestations of Wilson Disease Evaluated with the Unified Wilson's Disease Rating Scale

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2018 Apr 7
PMID 29621974
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Wilson disease is a rare genetic disorder in which impaired copper excretion results in toxic copper levels and tissue damage. Manifestations are primarily hepatic and/or neuropsychiatric, with a variety of neurological phenotypes. The aim of this study was to characterize neurological signs of Wilson disease in newly diagnosed patients and to determine whether they correlated with disability, liver function, and copper metabolism.

Methods: Fifty-three treatment-naïve patients recently diagnosed with Wilson disease who exhibited neurological symptoms were included. Neurological manifestations were characterized by examination in terms of symptom type and degree of neurological impairment (Unified Wilson's Disease Rating Scale [UWDRS] Part III) and correlated with degree of disability (UWDRS Part II), abnormalities in copper parameters and hepatic status.

Results: Most patients (62.3%) exhibited tremor and ataxia, whereas 15.1% were dystonic, and 11.3% had parkinsonism. Discrete or unclassified signs only were observed in 11.3% of patients. A good correlation between disability (UWDRS Part II) and neurological impairment (UWDRS Part III) was observed (Pearson r = 0.84). However, there was a lack of correlation when either disability or neurological impairment were analyzed with copper parameters or liver impairment.

Conclusions: The predominant neurological manifestations in this cohort of newly diagnosed Wilson disease patients were ataxia and tremor. Neurological impairment measured was highly correlated with the level of disability. However, hepatic manifestations of Wilson disease and copper levels did not appear to be correlated with neurological status and disability. These results highlight the challenges faced when assessing Wilson disease with its highly variable symptomatology.

Citing Articles

Early neurological deterioration in Wilson's disease: a systematic literature review and meta-analysis.

Antos A, Czlonkowska A, Smolinski L, Bembenek J, Przybylkowski A, Skowronska M Neurol Sci. 2023; 44(10):3443-3455.

PMID: 37311952 PMC: 10495500. DOI: 10.1007/s10072-023-06895-6.


Blood Based Biomarkers of Central Nervous System Involvement in Wilson's Disease.

Antos A, Czlonkowska A, Bembenek J, Skowronska M, Kurkowska-Jastrzebska I, Litwin T Diagnostics (Basel). 2023; 13(9).

PMID: 37174946 PMC: 10177361. DOI: 10.3390/diagnostics13091554.


Long-term outcome of patients with neurological form of Wilson's disease compliant to the de-coppering treatment.

Stankovic I, Jovanovic C, Vitkovic J, Svetel M, Pekmezovic T, Tomic A J Neurol. 2023; 270(7):3492-3498.

PMID: 37016067 DOI: 10.1007/s00415-023-11681-7.


Dysfunction of the Lenticular Nucleus Is Associated with Dystonia in Wilson's Disease.

Yang Y, Wei T, Yang W, Hu S, Jiang H, Dong W Brain Sci. 2023; 13(1).

PMID: 36671989 PMC: 9856696. DOI: 10.3390/brainsci13010007.


Autoantibodies in Wilson disease: Impact on clinical course.

Antczak-Kowalska M, Czlonkowska A, Eyileten C, Palejko A, Cudna A, Wolska M JIMD Rep. 2022; 63(5):508-517.

PMID: 36101827 PMC: 9458613. DOI: 10.1002/jmd2.12317.


References
1.
Weiss K, Askari F, Czlonkowska A, Ferenci P, Bronstein J, Bega D . Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol. 2017; 2(12):869-876. DOI: 10.1016/S2468-1253(17)30293-5. View

2.
Duncan A, Yacoubian C, Beetham R, Catchpole A, Bullock D . The role of calculated non-caeruloplasmin-bound copper in Wilson's disease. Ann Clin Biochem. 2016; 54(6):649-654. DOI: 10.1177/0004563216676843. View

3.
Volpert H, Pfeiffenberger J, Groner J, Stremmel W, Gotthardt D, Schafer M . Comparative assessment of clinical rating scales in Wilson's disease. BMC Neurol. 2017; 17(1):140. PMC: 5521125. DOI: 10.1186/s12883-017-0921-3. View

4.
Dhawan A, Taylor R, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G . Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 2005; 11(4):441-8. DOI: 10.1002/lt.20352. View

5.
Oder W, Prayer L, Grimm G, Spatt J, Ferenci P, Kollegger H . Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology. 1993; 43(1):120-4. DOI: 10.1212/wnl.43.1_part_1.120. View